Jubilant Biosys

Delivering the Added Dimension in Drug Discovery Services

8th May 2019

Jubilant Biosys Selects CDD Vault for Discovery Research Informatics

Jubilant Biosys and Collaborative Drug Discovery (CDD) announced today, following an exhaustive evaluation, Jubilant has chosen CDD Vault as their discovery research informatics platform for the next 5 years.

28th March 2019

Jubilant Biosys is First to add ForteBio’s latest SPR System in India

Jubilant Biosys announced today that it has added advanced Pioneer FE system to its platform of drug discovery solutions available to customers. The Pioneer FE system from ForteBio represents the next generation SPR instrumentation for label-free characterization of biomolecules.

13th February 2019

Jubilant Biosys expands collaboration with Sanofi in CNS Therapeutic Area

Collaboration aimed at discovery of small molecule inhibitors targeting neurological disorders.

29th November 2017

Jubilant Biosys Announces Early Milestone in Collaborative Discovery Program

Jubilant Biosys announced today that they successfully achieved an early stage milestone related to a collaborative program with Sanofi in Frankfurt, Germany focused on metabolic disorders.

19th September 2016

Jubilant Biosys Strengthens its Leadership Team with Two Key Appointments

Jubilant Biosys Ltd announced two new leadership appointments. Mr. Steven Hutchins has been appointed as President and Dr. Takeshi Yura has been appointed as Vice President of Medicinal Chemistry.

26th May 2016

Jubilant Biosys Enters into Exclusive out-Licensing Agreement with Checkpoint Therapeutics

Jubilant today announced the signing of an exclusive, worldwide license agreement under which Jubilant Biosys will out-license to Checkpoint a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for…

7th Jan 2016

Jubilant Biosys and Sanofi Deutschland GmbH enter into a Strategic Alliance

Collaboration aimed at discovery and development of small molecule inhibitors through to Phase I proof of mechanism in metabolic disorders therapeutic area.